PT  - JOURNAL ARTICLE
AU  - Adriana Roca-Fernández
AU  - Malgorzata Wamil
AU  - Alison Telford
AU  - Valentina Carapella
AU  - Alessandra Borlotti
AU  - David Monteiro
AU  - Helena Thomaides-Brears
AU  - Matthew D Kelly
AU  - Andrea Dennis
AU  - Rajarshi Banerjee
AU  - Matthew D. Robson
AU  - Michael Brady
AU  - Gregory Y. H. Lip
AU  - Sacha Bull
AU  - Melissa Heightman
AU  - Ntobeko Ntusi
AU  - Amitava Banerjee
TI  - Cardiac impairment in Long Covid 1-year post-SARS-CoV-2 infection
AID  - 10.1101/2022.04.03.22272610
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.04.03.22272610
4099  - http://medrxiv.org/content/early/2022/04/04/2022.04.03.22272610.short
4100  - http://medrxiv.org/content/early/2022/04/04/2022.04.03.22272610.full
AB  - Background Long Covid is associated with multiple symptoms and impairment in multiple organs. Cardiac impairment has been reported to varying degrees by varying methodologies in cross-sectional studies. Using cardiac magnetic resonance (CMR), we investigated the 12-month trajectory of cardiac impairment in individuals with Long Covid.Methods 534 individuals with Long Covid underwent baseline CMR (T1 and T2 mapping, cardiac mass, volumes, function, and strain) and multi-organ MRI at 6 months (IQR 4.3,7.3) since first post-COVID-19 symptoms and 330 were rescanned at 12.6 (IQR 11.4, 14.2) months if abnormal findings were reported at baseline. Symptoms, standardised questionnaires, and blood samples were collected at both timepoints. Cardiac impairment was defined as one or more of: low left or right ventricular ejection fraction (LVEF and RVEF), high left or right ventricular end diastolic volume (LVEDV and RVEDV), low 3D left ventricular global longitudinal strain (GLS), or elevated native T1 in ≥3 cardiac segments. A significant change over time was reported by comparison with 92 healthy controls.Results The technical success of this multiorgan assessment in non-acute settings was 99.1% at baseline, and 98.3% at follow up, with 99.6% and 98.8% for CMR respectively. Of individuals with Long Covid, 102/534 [19%] had cardiac impairment at baseline; 71/102 had complete paired data at 12 months. Of those, 58% presented with ongoing cardiac impairment at 12 months. High sensitivity cardiac troponin I and B-type natriuretic peptide were not predictive of CMR findings, symptoms, or clinical outcomes. At baseline, low LVEF, high RVEDV and low GLS were associated with cardiac impairment. Low LVEF at baseline was associated with persistent cardiac impairment at 12 months.Conclusion Cardiac impairment, other than myocarditis, is present in 1 in 5 individuals with Long Covid at 6 months, persisting in over half of those at 12 months. Cardiac-related blood biomarkers are unable to identify cardiac impairment in Long COVID. Subtypes of disease (based on symptoms, examination, and investigations) and predictive biomarkers are yet to be established. Interventional trials with pre-specified subgroup analyses are required to inform therapeutic options.Competing Interest StatementAB has received funding from NIHR (including the STIMULATE-ICP study), AstraZeneca, European Union, UK Research and Innovation and British Medical Association. Conflicts of interest: AD, AT, VC, ABo, SF, MP, ARF, HTB, MK, MR, MB and RB are employees of Perspectum.Clinical TrialNCT04369807Funding StatementThe study was partly financed by an Amendment to a European Commission Horizon 2020 grant 719445 (AMENDMENT Reference No AMD-719445-8): Non-invasive rapid assessment of chronic liver disease using Magnetic Resonance Imaging with LiverMultiScan (RADIcAL).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The protocol received full ethical approval from South Central - Berkshire B Research Ethics Committee (20/SC/0185) and was registered (https://clinicaltrials.gov/ct2/show/NCT04369807).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript